WHITE PAPER
Evolution of Treatment and Challenges in Multiple Myeloma
Sep 22, 2023

As the field has advanced, treating myeloma has become increasingly complex. The rise of triple-class refractory disease, for instance, has sparked a need for improved sequencing strategies and novel therapies. While MRD assessment and BCMA therapies are two potential solutions to these problems, they come with issues of their own which may impact their uptake. Therefore, even as we address the challenges of treating myeloma today, it remains important to anticipate and address the challenges the field may see tomorrow.

Related solutions

Contact Us